Policies to aid the adoption of personalized medicine

Nature Reviews Drug Discovery

Volumn 13, Issue 3, 2014, Pages 159-160

  Nofziger, Charity ^a   Papaluca, Marisa ^b   Terzic, Andre ^c   Waldman, Scott ^d   Paulmichl, Markus ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c MAYO CLINIC   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSULTATION; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; FUNDING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; NOTE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK BENEFIT ANALYSIS;

EUROPEAN UNION; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84895814542     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4257     Document Type: Note

References (3)

1. European Commission Working Document. [online], http://ec.europa.eu/ health/files/latestffnews/2013-10-personalisedffmedicineffen.pdf (2013
2. US Food and Drug Administration. [online], http://www.fda.gov/downloads/ scienceresearch/specialtopics/personalizedmedicine/ucm372421.pdf (2013
3. Maliepaard, M. et al. Nature Rev. Drug Discov. 12, 103-115 (2013